In the second quarter of 2026, the European Medicines Agency will launch a pilot programme to support breakthrough medical devices and in vitro diagnostics.

The aim is to test a pathway that accelerates patient access to highly innovative technologies, always maintaining the EU’s high standards for safety and performance.

Through the pilot, manufacturers of designated breakthrough devices will be able to benefit from enhanced regulatory support and priority scientific advice from the medical device expert panels administered by the European Medicines Agency.